A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

PHASE3CompletedINTERVENTIONAL
Enrollment

369

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Diabetic Peripheral NeuropathyPain
Interventions
DRUG

Capsaicin 8%

Capsaicin 8% transdermal delivery system

DRUG

Placebo

Placebo Patch

Trial Locations (29)

10029

Site:111, New York

27103

Site: 110, Winston-Salem

32765

Site: 132, Oviedo

32806

Site: 108, Orlando

33435

Site: 117, Boynton Beach

33458

Site: 120, Jupiter

33606

Site: 122, Tampa

33709

Site: 127, St. Petersburg

33765

Site: 107, Clearwater

34205

Site: 124, Bradenton

36207

Site: 125, Anniston

45429

Site: 121, Kettering

48104

Site: 115, Ann Arbor

63042

Site: 128, Hazelwood

75230

Site:106, Dallas

77030

Site: 118, Houston

77098

Site: 114, Houston

78228

Site: 105, San Antonio

78229

Site: 102, San Antonio

79410

Site: 103, Lubbock

90033

Site: 116, Los Angeles

90806

Site: 123, Long Beach

92868

Site: 112, Orange

93720

Site: 131, Fresno

94597

Site: 130, Walnut Creek

96814

Site: 133, Honolulu

06460

Site: 113, Milford

06320

Site: 119, New London

02740

Site: 126, New Bedford

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT01533428 - A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN) | Biotech Hunter | Biotech Hunter